Genmab A/S (NASDAQ:GMAB - Free Report) - Research analysts at HC Wainwright lifted their Q1 2025 earnings estimates for shares of Genmab A/S in a note issued to investors on Thursday, April 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.21 per share for the quarter, up from their prior estimate of $0.18. HC Wainwright has a "Buy" rating and a $37.00 price objective on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S's Q2 2025 earnings at $0.44 EPS, Q3 2025 earnings at $0.45 EPS and FY2026 earnings at $1.85 EPS.
A number of other research analysts also recently issued reports on the company. Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a report on Thursday, February 13th. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Truist Financial reduced their target price on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Finally, Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Genmab A/S presently has a consensus rating of "Moderate Buy" and a consensus price target of $39.17.
Check Out Our Latest Stock Report on GMAB
Genmab A/S Trading Up 1.4 %
Shares of Genmab A/S stock traded up $0.29 during trading on Friday, reaching $21.08. The stock had a trading volume of 845,376 shares, compared to its average volume of 1,509,329. The company has a market capitalization of $13.52 billion, a price-to-earnings ratio of 12.11, a P/E/G ratio of 2.65 and a beta of 1.07. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $30.41. The stock has a fifty day moving average price of $20.41 and a two-hundred day moving average price of $21.00.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%.
Hedge Funds Weigh In On Genmab A/S
Institutional investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC raised its holdings in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after buying an additional 939 shares in the last quarter. Lindbrook Capital LLC raised its holdings in Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after buying an additional 950 shares during the last quarter. GAMMA Investing LLC raised its holdings in Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after buying an additional 1,051 shares during the last quarter. Barclays PLC raised its holdings in Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after buying an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC raised its holdings in Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after buying an additional 2,496 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.
Genmab A/S Company Profile
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
See Also
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
